NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

J-To,



Thanks for yet another Henny Penny Chicken Little analysis, but all of your posts curiously seem like bad-faith attempts to induce panic … 🤔

NWBO does not depend on any lawsuit—the bedrock foundation of the company is the novel DCVax-L cell-based platform technology. The science and unmet medical need are the source of its value.

I had run your gem of a post through the detector 😶 …


“This statement appears to be an attempt to persuade by evoking fear. The poorly-reasoned argument is alarmist and baseless for several reasons:

1. **Speculative Assertions**: Claims like "Running out of funds" and "Huge dilution coming" are presented without evidence. Making such speculative assertions without backing them up with data or credible sources makes the statement baseless.

2. **Negative Predictions Without Basis**: Predicting "No immediate funds from the court case (maybe never)" and the need for a "Reverse Split to uplist and get institutional backing" is speculative. Legal and financial outcomes, especially in complex situations like court cases and stock listings, are uncertain and depend on numerous factors.

3. **Alarmist Tone**: The statement has an overall tone of urgency and doom, particularly in the phrase "She has backed NWBO into a very tight corner and had better do something real soon." This kind of language is designed to evoke fear and urgency rather than provide a balanced perspective or sound opinion.

4. **Lack of Context**: The statement lacks context and details that would be necessary to make a reasoned analysis of the situation. It presents a one-sided, negative view without considering other possible scenarios or interpretations.

5. **Assumption of Knowledge**: The statement assumes knowledge of the intentions and future actions of the company and its management, which is not typically available to the general public.

In summary, the statement's speculative nature, alarmist tone, and lack of substantiated facts make it unreliable and misleading as a source of information or analysis.”

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html